Henry Schein’s (HSIC) Outperform Rating Reiterated at Barrington Research

Barrington Research reissued their outperform rating on shares of Henry Schein (NASDAQ:HSIC) in a research report report published on Friday, Benzinga reports. Barrington Research currently has a $82.00 price objective on the stock.

Several other equities analysts have also issued reports on the company. JPMorgan Chase & Co. dropped their price target on Henry Schein from $88.00 to $80.00 and set an overweight rating on the stock in a research note on Monday, August 12th. Evercore ISI dropped their price target on Henry Schein from $72.00 to $70.00 and set an in-line rating on the stock in a research note on Wednesday, August 7th. UBS Group dropped their price target on Henry Schein from $75.00 to $72.00 and set a neutral rating on the stock in a research note on Wednesday, August 7th. Piper Sandler reissued an overweight rating and issued a $86.00 price target on shares of Henry Schein in a research note on Friday, June 21st. Finally, Baird R W raised Henry Schein from a hold rating to a strong-buy rating in a research note on Monday, July 22nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of Hold and a consensus target price of $77.10.

Henry Schein Trading Up 0.7 %

HSIC stock opened at $71.63 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.55 and a quick ratio of 0.90. The company has a fifty day moving average price of $70.00 and a two-hundred day moving average price of $70.29. Henry Schein has a one year low of $60.01 and a one year high of $82.63. The stock has a market cap of $9.17 billion, a price-to-earnings ratio of 24.20, a price-to-earnings-growth ratio of 1.88 and a beta of 0.86.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.01. The company had revenue of $3.10 billion during the quarter, compared to the consensus estimate of $3.27 billion. Henry Schein had a return on equity of 13.19% and a net margin of 2.82%. The company’s revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm earned $1.31 earnings per share. Equities analysts anticipate that Henry Schein will post 4.75 EPS for the current year.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the sale, the senior vice president now owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On Henry Schein

Institutional investors and hedge funds have recently bought and sold shares of the stock. Summit Securities Group LLC bought a new position in Henry Schein during the 2nd quarter worth approximately $31,000. Beach Investment Counsel Inc. PA bought a new position in Henry Schein during the 2nd quarter worth approximately $37,000. Blue Trust Inc. grew its position in Henry Schein by 104.2% during the 2nd quarter. Blue Trust Inc. now owns 931 shares of the company’s stock worth $60,000 after acquiring an additional 475 shares during the last quarter. Mather Group LLC. bought a new position in Henry Schein during the 1st quarter worth approximately $97,000. Finally, Palisade Asset Management LLC bought a new position in Henry Schein during the 1st quarter worth approximately $113,000. 96.62% of the stock is currently owned by institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.